Claire Madden-Smith joins BDD Pharma Board as Non-Executive Director
BDD PHARMA LIMITED
For immediate release – June 13th 2022
Claire Madden-Smith joins BDD Pharma Board as Non-Executive Director
BDD Pharma today announced the appointment of Claire Madden-Smith as Non-Executive Director of the Board.
Claire, who has more than 20 years experience in the pharmaceutical sector, was an Executive Director at Molecular Profiles Ltd and served as Senior Vice President at Juniper Pharma Services Ltd at the time of its sale to Catalent for $140m in 2018.
As a senior executive, Claire has proven success in delivering growth, building from a small spin out to an organisation with over 200 employees. She currently acts as an independent consultant to the investment community and to pharmaceutical companies, providing support on growth, investment strategies and due diligence.
This appointment expands the existing Board to 7 directors, 4 of whom are independent. Claire will play a significant role in supporting the strategic vision of BDD including the planned expansion of the Company’s GMP services.
Commenting on this appointment, Carol Thomson, CEO of BDD, said: “I am delighted to welcome Claire to the Board, her wealth of knowledge of the pharmaceutical sector and experience of strategic planning and operational growth strategies will be a huge boost to BDD as we embark on our next phase of expansion as a fully integrated formulation development and clinical trials company”
Commenting on her appointment, Claire said “I am pleased to be joining the board of BDD at this exciting stage of growth and expansion. BDD has an experienced team delivering an integrated clinical and development offering, much needed by the pharmaceutical sector and I look forward to helping them further refine their service positioning to support the development of products for unmet medical needs”
Further enquiries:
BDD Pharma Ltd
Notes to Editors
About BDD
BDD Pharma Ltd is a privately-owned CDMO drug delivery company specializing in the development of modified and controlled release oral formulations.
BDD Pharma combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products
Rapid parallel clinical testing with BDD SWIFT significantly reduces the time from product concept to clinical success.
Recognizing that one size does not fit all we specialise in providing responsive, flexible and innovative solutions to our customers.
For more information visit
